Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Michele Caraglia, Monica Marra, Silvio Naviglio, Gerardo Botti, Raffaele Addeo & Alberto Abbruzzese. (2010) Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opinion on Pharmacotherapy 11:1, pages 141-154.
Read now
Read now
Articles from other publishers (27)
Andrea Christou, Nuno Ferreira & Antonia Sophocleous. (2022) Effects of zoledronic acid on osteosarcoma progression and metastasis: systematic review and meta‐analysis. Clinical and Experimental Medicine 23:7, pages 3041-3051.
Crossref
Crossref
Aidan Kane, Leona Campbell, Diana Ky, David Hibbs & Dee Carter. (2021)
The Antifungal and Synergistic Effect of Bisphosphonates in
Cryptococcus
. Antimicrobial Agents and Chemotherapy 65:2.
Crossref
Crossref
Rachel M. Jones, Claire Morgan & Gianfilippo Bertelli. (2015) Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer. Tumor Biology 36:6, pages 4861-4869.
Crossref
Crossref
Umut Varol, Mustafa Degirmenci, Burcak Karaca, Harika Atmaca, Asli Kisim, Selim Uzunoglu, Canfeza Sezgin, Ulus Ali Sanli & Ruchan Uslu. (2014) Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines. Tumor Biology 36:2, pages 779-786.
Crossref
Crossref
Iris Chiara Salaroglio, Ivana Campia, Joanna Kopecka, Elena Gazzano, Sara Orecchia, Dario Ghigo & Chiara Riganti. (2014) Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. Oncotarget 6:2, pages 1128-1142.
Crossref
Crossref
Chiara Riganti, Barbara Castella, Joanna Kopecka, Ivana Campia, Marta Coscia, Gianpiero Pescarmona, Amalia Bosia, Dario Ghigo & Massimo Massaia. (2013) Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells. PLoS ONE 8:4, pages e60975.
Crossref
Crossref
Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Georgios Gakis, Ulrich Vogel, Stefan Aufderklamm, Axel Merseburger, Judith Knapp, Arnulf Stenzl & Christian Schwentner. (2012) Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?. World Journal of Urology 31:2, pages 345-350.
Crossref
Crossref
Jean-Baptiste Lattouf & Fred Saad. 2013. Prostate Cancer: A Comprehensive Perspective. Prostate Cancer: A Comprehensive Perspective
935
940
.
H K Koul, S Koul & R B Meacham. (2011) New role for an established drug? Bisphosphonates as potential anticancer agents. Prostate Cancer and Prostatic Diseases 15:2, pages 111-119.
Crossref
Crossref
Y. Loriot, C. Massard & K. Fizazi. (2012) Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Annals of Oncology 23:5, pages 1085-1094.
Crossref
Crossref
KOJIRO YANO. (2012) Lipid metabolic pathways as lung cancer therapeutic targets: A computational study. International Journal of Molecular Medicine 29:4, pages 519-529.
Crossref
Crossref
Matti Aapro & Fred Saad. (2012) Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Therapeutic Advances in Urology 4:2, pages 85-101.
Crossref
Crossref
Susanta K. Hui, Gregory R. Fairchild, Louis S. Kidder, Manju Sharma, Maryka Bhattacharya, Scott Jackson, Chap Le & Douglas Yee. (2011) Skeletal Remodeling Following Clinically Relevant Radiation-Induced Bone Damage Treated with Zoledronic Acid. Calcified Tissue International 90:1, pages 40-49.
Crossref
Crossref
Fred Saad & Jean-Baptiste Lattouf. 2012. Prevention of Bone Metastases. Prevention of Bone Metastases
109
126
.
Joaquim Bosch-Barrera, Sofía D. Merajver, Javier A. Menéndez & Catherine Van Poznak. (2011) Direct antitumour activity of zoledronic acid: preclinical and clinical data. Clinical and Translational Oncology 13:3, pages 148-155.
Crossref
Crossref
Jinlu Dai, Yi Lu, Chunyan Yu, Jill M. Keller, Atsushi Mizokami, Jian Zhang & Evan T. Keller. (2010) Reversal of Chemotherapy-Induced Leukopenia Using Granulocyte Macrophage Colony-Stimulating Factor Promotes Bone Metastasis That Can Be Blocked with Osteoclast Inhibitors. Cancer Research 70:12, pages 5014-5023.
Crossref
Crossref
Helen L. Neville-Webbe, Michael Gnant & Robert E. Coleman. (2010) Potential Anticancer Properties of Bisphosphonates. Seminars in Oncology 37, pages S53-S65.
Crossref
Crossref
Fred Saad & James Eastham. (2010) Maintaining Bone Health in Prostate Cancer Throughout the Disease Continuum. Seminars in Oncology 37, pages S30-S37.
Crossref
Crossref
H.L. Neville-Webbe & R.E. Coleman. (2010) Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. European Journal of Cancer 46:7, pages 1211-1222.
Crossref
Crossref
Robert Segal, Fadi Brimo & Wassim Kassouf. (2010) Normalization of Prostate-Specific Antigen and Reduction of Clinical Metastasis Following Zoledronic Acid Treatment in Castrate-Resistant Prostate Cancer. UroToday International Journal 03:01.
Crossref
Crossref
Stephen S. Grubbs & Charles J. Schneider. 2009. Bone and Cancer. Bone and Cancer
219
227
.
John M. Fitzpatrick, Marc Colombel, Fred Saad, Cora N. Sternberg & Andrea Tubaro. (2009) Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum. European Urology Supplements 8:9, pages 733-737.
Crossref
Crossref
Hervé Nyangoga, Stéphane Blouin, Hélène Libouban, Michel Félix Baslé & Daniel Chappard. (2009) A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat. Microscopy Research and Technique, pages NA-NA.
Crossref
Crossref
Francesco Fabbri, Giovanni Brigliadori, Silvia Carloni, Paola Ulivi, Ivan Vannini, Anna Tesei, Rosella Silvestrini, Dino Amadori & Wainer Zoli. (2008) Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. Journal of Translational Medicine 6:1.
Crossref
Crossref
Panagiotis Tsagozis, Fredrik Eriksson & Pavel Pisa. (2008) Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunology, Immunotherapy 57:10, pages 1451-1459.
Crossref
Crossref
Daniele Santini, Sara Galluzzo, Maria Elisabetta Fratto, Bruno Vincenzi, Silvia Angeletti, Giordano Dicuonzo, Gaia Schiavon & Giuseppe Tonini. (2008) Bisphosphonates: from preclinical evidence to survival data in the oncologic setting. Oncology Reviews 1:3, pages 141-151.
Crossref
Crossref
Yonghui Zhang, Michael P. Hudock, Kilannin Krysiak, Rong Cao, Kyle Bergan, Fenglin Yin, Annette Leon & Eric Oldfield. (2007) Activity of Sulfonium Bisphosphonates on Tumor Cell Lines. Journal of Medicinal Chemistry 50:24, pages 6067-6079.
Crossref
Crossref